ArticleSAGE open medical case reports2025
Unique genetic presentation of Gitelman syndrome in a Hispanic patient: Case report.
Article in SAGE open medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Gitelman's syndrome, also known as, familial hypokalemia-hypomagnesemia, is a renal tubulopathy responsible for salt wasting resulting in, hypomagnesemia, hypocalciuria, and secondary activation of the renin-angiotensin-aldosterone system, responsible for the hypokalemia and metabolic alkalosis. Gitelman's syndrome is due to a rare, autosomal recessive gene mutation due to deletions, missense, nonsense, frame-shift, and splice-site mutation in the solute carrier family 12, member 3 gene. Solute carrier family 12, member 3, encodes a thiazide-sensitive sodium-chloride cotransporter in the apical membrane of cells within the distal convoluted tubule, leading to the development of Gitelman's syndrome. An 18-year-old male patient with a past medical history of chronic hypokalemia, hypomagnesemia, and constipation presented to the clinic as a continuation of care from his pediatric nephrologist for previously diagnosed Gitelman's syndrome in his childhood. Regarding his history of Gitelman's syndrome leading up to his diagnosis, at the age of 3, the patient was found to be hypokalemic on routine testing with no identifiable cause. The patient underwent genetic testing, where the test result demonstrated a positive solute carrier family 12, member 3 gene mutation, concurrent with Gitelman's syndrome. On genetic testing, heterozygous variants were also detected c. 179C>T, which is a known disease-causing mutation. Currently, the patient is being monitored due to persistent hydronephrosis of the bilateral kidneys. The patient has constantly dealt with hydronephrosis; however, kidney function has been preserved. The c.179C>T (Thr60Met) variant has been used to identify individuals with Gitelman's syndrome due to this mutation being the most common, thought to be found in 1-10/40,000 individuals, with higher prevalence within Asian demographics. Literature shows a greater association of Japanese and Chinese descent when compared to other demographic groups. This finding in an individual of Hispanic origin should increase suspicion that this finding can be found in individuals, not of Asian descent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.